Cost-effectiveness of biologics as first-line treatment of rheumatoid arthritis: case closed?
Boers
Maarten
M
D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006801:Humans; D007155:Immunologic Factors / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007155:Immunologic Factors